Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 25 от 222

Набира участници

Providing Grandchild Care in Later Life

Child Care

Grandchild care is a modern global phenomenon arising from increased life expectancy , and, correlated with the rest of the world, the Turkish Statistical Institute's report on aging states that the prevalence of grandchild caregiving in Türkiye is 9.7% . Therefore, the health impacts of grandchild caregiving on older adults are attracting increasing attention. Various studies have shown that grandchild caregiving has both potential benefits and burdens for older individuals. While caregiving can provide physical activity, purpose, and emotional rewards, it can also create stress, reduce autonomy, and limit social participation and self-care, which is a significant determinant of healthy aging. Frailty, a multidimensional geriatric syndrome, is associated with disability, hospitalization, and death and is potentially reversible if diagnosed early. Furthermore, depression is another significant geriatric syndrome in the elderly and is associated with mortality; although various studies have shown that grandchild caregiving reduces depressive symptoms, some have found no association between grandchild caregiving and depression. The aim of this study is to investigate the relationship between grandchild care and frailty, depression, and self-neglect in patients presenting to geriatrics outpatients

Начало: 30.03.2026 Край: 30.05.2026 Възраст: от 60 г.

Turkey (Türkiye) Mersin University NCT07501260

Набира участници

Investigation of Patients Presenting With Acute Functional Neurological Symptoms

Functional Neurological Disorder

Retrospective Single-center Analysis of Patients Presenting With Acute Neurological Symptoms, Aiming to Characterize the Frequency, Clinical Features, Diagnostic Pathways, and Healthcare Utilization of Patients with Functional Neurological Diseases

Начало: 30.03.2026 Край: 01.12.2050 Възраст: от 16 г.

Switzerland University Hospital, Basel, Switzerland NCT07538414

Набира участници Фаза 1

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Cytomegalovirus Prophylaxis

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it

Начало: 30.03.2026 Край: 19.05.2028 Възраст: до 17 г.

United States Merck Sharp & Dohme LLC NCT07199465

Набира участници Фаза 1/2

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Advanced Solid Tumor Cancer

This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.

Начало: 30.03.2026 Край: 01.10.2030 Възраст: от 18 г. Лечение

Australia, China, Taiwan BioNTech SE NCT07455734

Набира участници Фаза 2

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Extensive Stage Lung Small Cell Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide. Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time. Ivonescimab is a new drug that may help the immune system attack cancer cells and may also block certain pathways that cancer uses to grow and spread. This dual action of ivonescimab aims to help the immune system to fight the cancer and also disrupt tumor growth by blocking blood vessel formation that tumors use to grow. Participants will receive induction with 4 cycles of ivonescimab (dose determined by randomization) with standard of care carboplatin and etoposide followed by maintenance therapy with ivonescimab at the same dose received during induction. Treatment will continue until disease progression, unacceptable toxicity or participant withdrawal. The purpose of this study is to determine what dose of ivonescimab works best in combination with carboplatin and etoposide chemotherapy in ES-SCLC. We will also examine the side effects, good and bad, associated with ivonescimab.

Начало: 30.03.2026 Край: 01.01.2030 Възраст: от 18 г.

United States PrECOG, LLC. NCT07057791

Набира участници Фаза 2

Phase II study to improve sacituzumab govitecan tolerance with atropine in patients with advanced triple-negative and hormone receptor-positive/HER2-negative breast cancer (The SATROPIN Study).

Advanced triple-negative breast cancer (TNBC)

Trial status: Authorised Overall safety profile according to the NCI-CTCAE v.5.0 during the first two treatment cycles and the extended follow-up., Incidence of all grades diarrhea during the first two treatment cycles and during the extended follow-up, as assessed by the Investigator, with severity determined by NCI-CTCAE v.5.0., Incidence of all grades constipation during the first two treatment cycles and during the extended follow-up, as assessed by the Investigator, with severity determined by NCI-CTCAE v.5.0., Dose reduction rate, defined as the proportion of participants with dose reduction due to toxicity relative to the number of participants in the analysis set., Dose interruption rate, defined as the proportion of participants with dose interruption due to toxicity relative to the number of participants in the analysis set., Discontinuation rate, defined as the proportion of participants who discontinued Study treatment to any cause relative to the number of participants in the analysis set., rwPFS, defined as the time between start of treatment to date of disease progression or death documented in participant medical charts, whichever date came first., TTF, defined as the time from the start of treatment to its discontinuation for any reason, including disease progression, treatment-related toxicity, participant withdrawal, or death., TTF-Toxicity, defined as the time from the start of treatment to its discontinuation especially due to treatment-related adverse events (TEAEs). It excludes discontinuation for other reasons such as disease progression, participant withdrawal, or death unrelated to toxicity., OS, defined as the period from treatment initiation to death from any cause, as determined locally by the Investigator., Incidence of all grades constipation during the first two treatment cycles, as assessed by the Investigator, withseverity determined by the NCI-CTCAE v.6.0. Incidence of grade ≥2 diarrhea during the first two treatment cycles as assessed by the Investigator, with severity determined by the NCI-CTCAE v.5.0.

Начало: 30.03.2026 Възраст: от 18 г.

Portugal, Spain Medica Scientia Innovation Research S.L. 2025-524109-33-00

Набира участници

Routine Probe Compression After Transrectal Prostate Biopsy(RPCAB) to Reduce Bleeding and Infectious Complications : A Randomized Controlled Trial

Prostate Biopsy Post Biopsy Bleeding Transrectal Ultrasound-guided Prostate Biopsy

Hematuria (up to 50%) and rectal bleeding (up to 30%) are common complications following transrectal ultrasound-guided prostate biopsy. Although most cases are mild, some require additional intervention. Short-duration compression has been shown to achieve hemostasis in cases of post-biopsy bleeding, suggesting that routine probe compression may reduce bleeding complications. Post-biopsy bleeding may also be associated with an increased risk of subsequent infection. This randomized controlled trial aims to evaluate the effect of routine probe compression and compression duration after transrectal prostate biopsy on bleeding and infectious complications.

Начало: 30.03.2026 Край: 28.02.2027 Възраст: от 18 г.

South Korea Veterans Health Service Medical Center, Seoul, Korea NCT07550985

Набира участници

Virtual Reality for Postoperative Recovery After Major Abdominal Surgery

Abdominal Surgery Postoperative Recovery Postoperative Pain Length of Hospital Stay

Major abdominal surgery often leads to significant postoperative pain, anxiety, and prolonged hospital stays, which can delay overall recovery. This study aims to evaluate the effectiveness of immersive Virtual Reality (VR) as a non-pharmacological intervention to enhance the quality of recovery and reduce the length of hospital stay. Patients in the intervention group will engage in standardized VR sessions featuring guided relaxation and mindfulness-based stress reduction, starting from the evening before surgery through the third postoperative day. The study compares this VR-enhanced protocol against standard perioperative care within an Enhanced Recovery After Surgery (ERAS) framework. The findings are expected to determine if VR can serve as a feasible and effective tool to improve clinical outcomes and patient well-being in surgical wards.

Начало: 28.03.2026 Край: 01.05.2026 Възраст: 18–60 г.

Egypt Alexandria University NCT07493499

Набира участници

Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

Pancreas Cancer

This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.

Начало: 27.03.2026 Край: 01.01.2029 Възраст: от 18 г.

France Institut Bergonié NCT06705335

Набира участници

Rapid Non-Invasive Brain Stimulation for Hoarding Disorder

Hoarding Disorder Hoarding Clutter

This study explores whether rapid non-invasive brain stimulation can help reduce hoarding disorder symptoms.

Начало: 27.03.2026 Край: 01.01.2028 Възраст: 18–70 г.

United States Stanford University NCT06712914

Набира участници Фаза 2/3

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Macular Degeneration Age-Related Macular Degeneration Choroidal Neovascularization Wet Macular Degeneration

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Начало: 27.03.2026 Край: 30.06.2028 Възраст: от 50 г.

United States EyeBiotech Ltd. NCT07440225

Набира участници Фаза 1/2

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Oesophageal Squamous Cell Carcinoma

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.

Начало: 27.03.2026 Край: 12.06.2028 Възраст: от 18 г.

Japan, South Korea, Taiwan Merck Sharp & Dohme LLC NCT07405151

Набира участници Фаза 3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Nausea and Vomiting Obesity

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Начало: 27.03.2026 Край: 01.12.2026 Възраст: 18–65 г.

United States Vanda Pharmaceuticals NCT07446439

Набира участници

Advanced vs Standard Hemodynamic Monitoring During Propofol Sedation for ERCP: A Prospective Study

Hemodynamic Instability

The aim of this study is to evaluate whether there is a difference in hemodynamic events requiring intervention between patients monitored with advanced hemodynamic monitoring using the MostCare system and those monitored with standard monitoring alone during propofol sedation for ERCP procedures.

Начало: 27.03.2026 Край: 15.05.2026 Възраст: от 18 г.

Turkey (Türkiye) Hitit University NCT07538115

Набира участници

Characterization of Nociception Phenotype in Individuals With Intellectual Disability

Intellectual Disability

Background: People with intellectual disability (ID) often have physical disabilities as well. These physical problems can affect their bones, muscles, nerves, and gastrointestinal tracts. All of these issues can also cause pain. Yet little research has been done on pain in people with ID. Objective: To compare brain responses to unpleasant stimuli in people with and without ID. Eligibility: People aged 8 to 30 years diagnosed with an ID. Healthy volunteers without an ID are also needed. Design: The study requires only 1 visit of up to 4 hours. Participants with ID may come for up to 5 shorter visits instead. Participants will take a test to measure their level of ID. They will have a physical exam. Both groups will answer questions about pain and how their bodies react to it. They will answer questions about how they respond to things they see, feel, hear, smell, and taste. They will answer questions about their social behaviors. Caregivers may answer questions if the participant cannot. Both groups will have a test to measure their brain activity. Participants will wear a special cap, like a swim cap, with sensors and wires. Sensors to examine the heart will be placed on the skin of their chest with stickers. An elastic band will be placed around the middle of their body to measure how fast they are breathing. Sensors to measure sweat will be placed on two fingers. Participants will have heat, cold, brushing, and mild electrical stimuli to different parts of their body. Participants will rank how each stimulus feels using a scale with numbers or a scale with faces.

Начало: 27.03.2026 Край: 06.10.2026 Възраст: 8–30 г.

United States National Institutes of Health Clinical Center (CC) NCT05473429

Набира участници Фаза 2

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Obesity & Overweight Mobility Disability HOMA-IR

The primary objective of this study is to assess the effect of enobosarm on total body weight

Начало: 26.03.2026 Край: 01.12.2027 Възраст: 65–100 г.

United States Veru Inc. NCT07446998

Набира участници

Usability of the Regen Gait Therapy Robot in Healthy Adults

Healthy Adult Participants

Regen is a robot-assisted device designed to help therapists and improve the quality of treatment. It works by replicating the movement of the therapist and providing assistance as needed for the patient. This study aims to assess the safety, feasibility, usability, and ability to Regen to replicate the movement pattern of therapist in young healthy adults during treadmill walking.

Начало: 26.03.2026 Край: 01.06.2026 Възраст: 18–50 г.

United States University of Texas at Austin NCT07547683

Набира участници

Testing a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health

Autism Challenging Behavior ADHD Oppositional Defiant Disorder

The goal of this clinical trial is to test whether a smartphone-based data collection and feedback application ("Footsteps") improves the quality of behavioral data collected by one-to-one aides and leads to better youth mental health outcomes in school-aged youth (ages 4-17) who receive one-to-one support in schools. The main questions it aims to answer are: 1. Does the Footsteps app improve aides' data collection quality (i.e., consistency, timeliness, and completeness)? 2. Does Footsteps use lead to improved youth behavioral health outcomes (e.g., SDQ, YTP, GAS scores)? 3. Does Footsteps improve communication and supervision processes between aides and clinical supervisors? Researchers will compare aides using Footsteps to those using a "data collection only" control app to see if Footsteps leads to higher quality data collection, enhanced supervisory communication, and better youth outcomes. Participants will: * Use either Footsteps or a control app to record de-identified data on one client's behaviors and skills over 12 weeks * Complete biweekly online surveys about data collection experiences, youth progress, and aide-supervisor communication * Participate in a virtual intake and post-trial meeting * (For a subset) Participate in a 30-45 minute qualitative interview about their experience using the app

Начало: 26.03.2026 Край: 30.06.2028 Възраст: от 18 г.

United States University of Pennsylvania NCT07042347

Набира участници Фаза 2/3

Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia

Radiation-induced Lung Injury Immune-related Pneumonia

Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinical use of immune-checkpoint inhibitors (ICIs) has further increased pulmonary toxicity when radiotherapy (RT) is combined with ICIs. Checkpoint-inhibitor-related pneumonitis (CIP)-i.e., immune-mediated lung injury-may necessitate permanent discontinuation of ICIs, diminish survival benefit, and, in severe cases, directly threaten life. The diagnosis of both RILI and CIP is based on an integrated assessment of subjective symptoms and imaging findings.RILI typically occurs 1-3 months after completion of radiotherapy, whereas CIP may emerge at any point during treatment. The two entities share similar clinical presentations: fever, dry cough, chest tightness, dyspnoea, and pleuritic chest pain. Computed tomography (CT) is the most sensitive imaging modality. Pulmonary-function testing is another routinely used clinical metric; vital capacity, total lung capacity, forced expiratory volume in 1 s (FEV₁), and diffusing capacity of the lung for carbon monoxide (DLCO) may all decline, with DLCO being the most sensitive parameter. In advanced cases, arterial oxygen and carbon-dioxide tensions may also deteriorate.Currently, RILI is managed empirically with systemic corticosteroids and supportive care; however, this approach yields limited improvement in diffusing capacity or ventilatory function, and its ability to prevent radiation-induced pulmonary fibrosis (RPF) remains undefined. Corticosteroids also remain the mainstay of CIP therapy. Pirfenidone, a potent cytokine inhibitor, attenuates fibroblast activity by reducing production of transforming growth factor-β1 (TGF-β1), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), thereby suppressing fibroblast proliferation and extracellular-matrix collagen synthesis. Pre-clinical efficacy studies have demonstrated robust anti-inflammatory, anti-oxidant, and anti-fibrotic effects in the lung.Because RILI and pneumonitis arising from combined radio-immunotherapy are often indistinguishable in clinical practice, and because both share pathogenetic features with idiopathic pulmonary fibrosis (IPF), the investigators initiated this phase II/III trial to address the unmet medical need for effective therapy. Building on prior pre-clinical and clinical data, the study aims to establish the optimal dose of pirfenidone capsules for RILI with or without concomitant CIP and to confirm efficacy and safety.Phase II (dose-finding): The study consists of a screening period (Day -28 to Day -1), a 168-day treatment-observation period (Day 1-Day 168), a safety follow-up (28 ± 7 days after the last dose), and subsequent disease-progression and survival follow-up. Ninety subjects with RILI, with or without CIP, who meet all eligibility criteria will be randomly assigned 1:1:1 to low-dose pirfenidone (400 mg TID), high-dose pirfenidone (600 mg TID), or matching placebo.Phase III (confirmatory): The dose of pirfenidone capsules for phase III will be determined jointly by the sponsor and investigators based on accumulated efficacy and safety data. The trial structure mirrors phase II: screening (Day -28 to Day -1), 168-day treatment-observation (Day 1-Day 168), safety follow-up (28 ± 7 days after the last dose), and disease-progression and survival follow-up. Eligible subjects with RILI ± CIP will be randomized 1:1 to receive either pirfenidone capsules (400 mg or 600 mg TID, taken with meals) or identical placebo. After completion of the 28-day post-treatment follow-up, all phase III participants will enter an extension phase for long-term survival assessment every 3 months (± 7 days).This trial will investigate the progression-free survival (PFS) and overall survival (OS) associated with pirfenidone capsules in patients with Grade 2 and 3 radiation-induced lung injury (RILI), with or without chemotherapy-induced pneumonitis (CIP).

Начало: 26.03.2026 Край: 30.12.2026 Възраст: 18–75 г.

China Beijing Continent Pharmaceutical Co, Ltd. NCT07388680

Набира участници Фаза 2

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

HER2-positive Early-stage Breast Cancer

This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biomarker assay, HER2 Activation Response Predictive Signature (HARPS) to identify HARPS-positive breast cancers. To assess 3-year invasive disease-free survival (iDFS) in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer. To correlate changes in ctDNA with treatment outcomes in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer. To understand the changes in quality of life (QOL) measure in patients with HARPS-positive HER2-positive breast cancer treated using an adaptive neoadjuvant trial design.

Начало: 26.03.2026 Край: 30.06.2028 Възраст: 18–90 г.

United States Rutgers, The State University of New Jersey NCT07402473

1 … 23 24 25 26 27 … 222